论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zheng XC, Ren W, Zhang S, Zhong T, Duan XC, Yin YF, Xu MQ, Hao YL, Li ZT, Li H, Liu M, Li ZY, Zhang X
Received 15 November 2017
Accepted for publication 25 January 2018
Published 13 March 2018 Volume 2018:13 Pages 1495—1504
DOI https://doi.org/10.2147/IJN.S157082
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Background: In
the present study, the tumor-specific, pH-responsive peptide H7K(R2)2 -modified, theranostic liposome-containing paclitaxel (PTX) and
superparamagnetic iron oxide nanoparticles (SPIO NPs), PTX/SPIO-SSL-H7K(R2)2, was prepared by using H7K(R2)2 as the targeting ligand, SPIO NPs as the magnetic resonance
imaging (MRI) agent, PTX as antitumor drug.
Methods: The PTX/SPIO-SSL-H7K(R2)2 was prepared by a thin film hydration method. The characteristics of
PTX/SPIO-SSL-H7K(R2)2 were evaluated.
The targeting effect, MRI, and antitumor activity of PTX/SPIO-SSL-H7K(R2)2 were investigated detail in vitro and in vivo in human breast
carcinoma MDA-MB-231 cell models.
Results: Our results of in vitro flow cytometry, in vivo imaging, and in
vivo MR imaging confirmed the pH-responsive characteristic of H7K(R2)2 in MDA-MB-231 cell line in vitro and in vivo. The results of
in vivo MRI and in vivo antitumor activity confirmed the theranostic effect of
PTX/SPIO-SSL-H7K(R2)2 in MDA-MB-231
tumor-bearing model.
Conclusion: Considering all our in vitro and in vivo results, we conclude that
we developed targeting modified theranostic liposome which could achieve both
role of antitumor and MRI.
Keywords: tumor-specific pH-responsive peptide, paclitaxel,
superparamagnetic iron oxide nanoparticles, liposome, theranostic efficiency